「the 20」の検索結果
143件：81～85件目を表示
-
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Atsuhiro Kanda ARVO 2026 開催日：...
http://www.senju.co.jp/english/rd/society/ -
da Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease treatment, SJP-0132 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, J...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117_0.pdf -
. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of 3in1Smart (Japanese medical device certification No. 307ADBZX00095000)...
https://www.senju.co.jp/system/files/content_news/2026-05/ENG_20260601_0.pdf -
. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of 3in1Smart (Japanese medical device certification No. 307ADBZX00095000)...
https://www.senju.co.jp/system/files/content_news/2026-05/ENG_20260601.pdf -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
Colorado, United States of America Inhibitory effect of a novel TRPV1 antagonist, motugivatrep, on the inflammatory response in dendritic cells Tsukasa Yagi, Mari Isomi, Atsuhiro Kanda ARVO 2026 開催日：...
https://www.senju.co.jp/english/rd/society/